NMN and Grip Strength: A Biomarker of Aging

NMN and Grip Strength have become a focal point in aging research because grip strength is one of the most reliable predictors of mortality, disability, and biological age. Unlike subjective measures of vitality, a hand dynamometer gives a quantifiable readout of neuromuscular function, and it declines predictably as NAD⁺ levels fall. Understanding whether nicotinamide mononucleotide (NMN) can influence this biomarker requires looking at the human trials that actually measured muscle performance, not just surrogate markers in cells or rodents.

Why Grip Strength Matters

Grip strength is not merely about hand power. It reflects the integrity of the entire neuromuscular axis, from cortical drive to muscle fiber contractility. Large epidemiological studies have consistently shown that lower grip strength predicts higher all-cause mortality, slower walking speed, and greater hospitalization risk. For researchers studying NAD⁺ biology, this makes grip strength an attractive functional endpoint: if NMN truly restores aspects of muscle physiology, it should eventually show up in something as simple as how hard a person can squeeze.

However, most NMN human trials were not designed with grip strength as a primary outcome. They focused on insulin sensitivity, blood NAD⁺ levels, or aerobic capacity. The connection between NMN and Grip Strength therefore rests on mechanistic inference plus a limited set of muscle function data from related studies. This is important context. We are not looking at a large body of direct evidence; we are looking at a plausible signal that needs stronger confirmation.

The Evidence Base

Only a handful of randomized controlled trials in humans have tested NMN for muscle-related outcomes, and none used grip strength specifically as a primary endpoint. The closest data come from studies that measured muscle insulin sensitivity, walking speed, or general muscle function in older adults.

Yoshino et al. (2021) conducted a randomized, placebo-controlled, crossover trial in postmenopausal women with prediabetes. Participants received 250 mg NMN daily for 10 weeks. The primary endpoint was muscle insulin sensitivity, measured via hyperinsulinemic-euglycemic clamp. NMN significantly improved insulin-stimulated glucose disposal, suggesting enhanced muscle metabolic health. Grip strength was not reported, but improved insulin signaling in muscle is a prerequisite for maintaining contractile function over time.

Igarashi et al. (2022) took a more direct approach. In a randomized, double-blind, placebo-controlled trial, 42 healthy older men received 250 mg NMN daily for 12 weeks. The study assessed muscle function using a 30-second chair stand test, 5-meter walking speed, and grip strength. The NMN group showed significant improvements in gait speed and lower-extremity function compared with placebo. Grip strength results were mixed and did not reach statistical significance in the overall analysis, though subgroup trends suggested some benefit in participants with lower baseline performance. Blood NAD⁺ and related metabolite levels rose significantly, confirming target engagement.

Irie et al. (2020) provided early safety and pharmacokinetic data in 10 healthy Japanese men. A single oral dose of 100, 250, or 500 mg NMN was well tolerated, with dose-dependent increases in blood NMN and NAD⁺ metabolites. No muscle function tests were included, but this study established the dosing range that later trials would adopt.

Liao et al. (2021) studied NMN in amateur runners, a younger and fitter population. Participants received 300, 600, or 1200 mg NMN daily for 6 weeks. The 600 and 1200 mg groups showed improved oxygen utilization and ventilatory thresholds, indicating better aerobic muscle metabolism. Grip strength was not measured, but the trial demonstrated that NMN can enhance muscle bioenergetics in humans under physical load.

Niu et al. (2023) examined a pre-aging cohort with a focus on serum metabolism, gut microbiota, and telomere length. NMN supplementation altered metabolic profiles in directions consistent with improved cellular energy status, but no direct muscle performance data were collected.

Study	Design	Population	NMN Dose	Duration	Muscle-Related Outcome	Direct Grip Strength Data
Yoshino et al. (2021)	RCT, crossover	Prediabetic women, postmenopausal	250 mg/day	10 weeks	Improved muscle insulin sensitivity	Not measured
Igarashi et al. (2022)	RCT, parallel	Healthy older men	250 mg/day	12 weeks	Improved gait speed, lower-extremity function	Mixed; not significant overall
Irie et al. (2020)	Single-dose escalation	Healthy Japanese men	100–500 mg single dose	Acute	Safety and pharmacokinetics only	Not measured
Liao et al. (2021)	RCT, parallel	Amateur runners	300–1200 mg/day	6 weeks	Improved aerobic capacity	Not measured
Niu et al. (2023)	RCT	Pre-aging adults	Not specified in abstract	Short-term	Metabolic profile changes	Not measured

The table makes the situation clear: only one trial, Igarashi et al. (2022), collected grip strength data at all, and the results were inconclusive. The case for NMN and Grip Strength is therefore suggestive but not proven. Anyone claiming definitive muscle-strengthening effects from NMN in humans is overstating the evidence.

The Mechanism

To understand why NMN might affect grip strength, we need to look at NAD⁺ biology in muscle. NAD⁺ is a coenzyme that sits at the intersection of energy metabolism, DNA repair, and cellular signaling. It is required for the function of sirtuins, PARPs, and NADPH oxidases, and it serves as the electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation.

Gomes et al. (2013) demonstrated that NAD⁺ decline during aging disrupts nuclear-mitochondrial communication. In their model, falling NAD⁺ levels reduced the activity of nuclear sirtuins, leading to a pseudohypoxic state in which cells behaved as if oxygen were scarce even when it was plentiful. This impaired mitochondrial function, reduced oxidative phosphorylation, and shifted muscle metabolism toward less efficient pathways. Restoring NAD⁺ through NMN precursors reversed these changes in aged mice, improving muscle function.

In human muscle, the logic follows similarly. If NMN raises NAD⁺ levels, it should support mitochondrial ATP production, enhance sirtuin-mediated maintenance of neuromuscular junctions, and improve the metabolic flexibility that underpins sustained muscle contraction. Grip strength depends on type II muscle fiber recruitment, calcium handling, and neural drive, all of which are energetically demanding. A NAD⁺-depleted muscle is a metabolically compromised muscle, even if structural damage is not yet visible.

However, mechanistic plausibility does not guarantee clinical efficacy. Mouse muscle is not human muscle. The doses that work in rodents, adjusted for body weight, often do not translate directly. And the duration of supplementation needed to rebuild functional reserve in aged human muscle may be longer than the 10–12 weeks typical of current trials.

What the Evidence Does Not Show

It is equally important to be clear about the gaps. No human trial has shown that NMN increases grip strength in a statistically robust, primary-endpoint fashion. The Igarashi et al. (2022) trial came closest and found improvement in gait speed and lower-extremity function, but grip strength itself did not separate from placebo in the full analysis. This could mean several things: the dose was too low, the duration too short, the population too healthy, or the measurement too noisy.

There is also no evidence that NMN benefits strength in young, already-fit individuals. Liao et al. (2021) showed aerobic gains in runners, but these are not strength gains. Muscle power and muscle endurance are partially distinct physiologically, and NAD⁺ repletion may influence one more than the other depending on training status and baseline NAD⁺ levels.

Finally, no trial has directly compared different NMN doses for muscle strength. The 250 mg/day used in most trials was chosen for feasibility and safety, not for maximal efficacy. Whether a higher dose, such as the 1000 mg found in some commercial formulations, would yield different muscle outcomes is unknown in the published literature. This is a relevant consideration when evaluating NMN and Muscle Recovery or broader functional goals.

Who Benefits Most

Based on the existing evidence, the populations with the strongest theoretical rationale for NMN supplementation are those with demonstrably low NAD⁺ and declining muscle function. This includes older adults, sedentary individuals, and those with metabolic conditions that accelerate NAD⁺ depletion. The Yoshino et al. (2021) trial focused on prediabetic women, a group with both insulin resistance and early sarcopenia risk, and saw meaningful metabolic improvements. The Igarashi et al. (2022) trial enrolled healthy older men and found functional benefits in lower-extremity tests, with trends toward better grip strength in weaker participants.

Young, healthy, physically active people probably have less to gain in terms of raw strength. Their NAD⁺ levels are likely near-optimal, and their muscle function is maintained by activity itself. For this group, NMN may still offer subtle metabolic or recovery advantages, but grip strength is unlikely to be the metric that moves.

Those interested in a broader view of how functional markers fit into aging assessment can consult the Longevity Biomarkers Guide. Grip strength is one of several practical tests, alongside gait speed and chair-rise time, that together predict biological age more accurately than any single measure.

Practical Takeaways

• Grip strength is a validated, low-cost biomarker of aging and mortality risk, but it has not been conclusively shown to improve with NMN in human trials.
• Only one published RCT, Igarashi et al. (2022), collected grip strength data after NMN supplementation; the results were mixed and not significant in the primary analysis.
• The biochemical rationale for NMN supporting muscle function is strong, grounded in NAD⁺-dependent energy metabolism and mitochondrial maintenance, but human translation remains incomplete.
• Doses of 250 mg/day have been most studied for muscle-related outcomes; whether higher doses yield greater functional benefits is an open question not addressed in current literature.
• Older adults with low baseline muscle function or metabolic impairment appear to show the most promising signals, while young, fit individuals have weaker theoretical rationale for strength gains.
• Anyone considering NMN for muscle or aging goals should view it as a long-term metabolic support strategy, not a rapid strength intervention. Consistent supplementation over months, combined with resistance training, is the most evidence-aligned approach.

Bottom Line

The link between NMN and Grip Strength is biologically plausible and indirectly supported by trials showing improved muscle metabolism and gait speed, but direct, robust evidence that NMN increases grip strength in humans does not yet exist. The field needs larger, longer trials with grip strength as a predefined endpoint before any firm claims can be made. Until then, NMN remains a promising NAD⁺ precursor with proven target engagement, best viewed as part of a broader strategy for maintaining muscle function with age rather than a standalone strength solution.

For readers exploring how NMN fits into the broader picture of physical decline, the article on NMN and Frailty in Aging examines related functional outcomes in more detail. Those selecting a product should consider form and dose transparency; for example, a formulation delivering 1000 mg of NMN per serving, such as Bio:sudo NMN 1000mg, offers a higher dose than most research trials have tested, though clinical outcomes at this level remain to be published.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---